Browse TNFSF13B

Summary
SymbolTNFSF13B
Nametumor necrosis factor (ligand) superfamily, member 13b
Aliases BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location13q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type II membrane protein.; SUBCELLULAR LOCATION: Tumor necrosis factor ligand superfamily member 13b, soluble form: Secreted.
Domain PF00229 TNF(Tumour Necrosis Factor) family
Function

Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the B-cell response. ; FUNCTION: Isoform 2 seems to inhibit isoform 1 secretion and bioactivity. ; FUNCTION: Isoform 3: Acts as a transcription factor for its own parent gene, in association with NF-kappa-B p50 subunit, at least in autoimmune and proliferative B-cell diseases. The presence of Delta4BAFF is essential for soluble BAFF release by IFNG/IFN-gamma-stimulated monocytes and for B-cell survival. It can directly or indirectly regulate the differential expression of a large number of genes involved in the innate immune response and the regulation of apoptosis.

> Gene Ontology
 
Biological Process GO:0001776 leukocyte homeostasis
GO:0001782 B cell homeostasis
GO:0002250 adaptive immune response
GO:0002260 lymphocyte homeostasis
GO:0002377 immunoglobulin production
GO:0002440 production of molecular mediator of immune response
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002467 germinal center formation
GO:0002634 regulation of germinal center formation
GO:0002636 positive regulation of germinal center formation
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0007159 leukocyte cell-cell adhesion
GO:0009306 protein secretion
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030888 regulation of B cell proliferation
GO:0030890 positive regulation of B cell proliferation
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0031296 B cell costimulation
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034612 response to tumor necrosis factor
GO:0042098 T cell proliferation
GO:0042100 B cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042129 regulation of T cell proliferation
GO:0045785 positive regulation of cell adhesion
GO:0046651 lymphocyte proliferation
GO:0048305 immunoglobulin secretion
GO:0048872 homeostasis of number of cells
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050863 regulation of T cell activation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050871 positive regulation of B cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071356 cellular response to tumor necrosis factor
GO:0071593 lymphocyte aggregation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005164 tumor necrosis factor receptor binding
GO:0032813 tumor necrosis factor receptor superfamily binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04064 NF-kappa B signaling pathway
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-5676594: TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
R-HSA-5669034: TNFs bind their physiological receptors
Summary
SymbolTNFSF13B
Nametumor necrosis factor (ligand) superfamily, member 13b
Aliases BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location13q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNFSF13B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TNFSF13B and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27364554Melanoma; Lung carcinomaPromote immunity (T cell function)BAFF and APRIL derived from activin A-treated DCs upregulate proliferation and survival of T cells expressing the corresponding receptors, BAFF-R and TACI. In vivo, activin A-stimulated DCs demonstrate a significantly increased ability to induce tumor-specific CTLs and inhibit the growth of melanoma and lung carcinoma, which relies on DC-derived BAFF and APRIL, as knockdown of the BAFF and APRIL gene expression in activin A-treated DCs blocks augmentation of their antitumor potential.
19366834Prostate carcinomaPromote immunityThe transition from normal to neoplastic glands in prostate cancer (PCa) is marked by a dramatic decline of IL-7 and BAFF/BLyS production. These results suggest that epithelial IL-7 and BAFF/BLyS production support intraprostatic lymphocyte survival.
19755673Chronic Lymphocytic LeukemiaInhibit immunityTCL1 x BAFF-Tg mice developed CLL-like disease at a significantly younger age and had more rapid disease progression and shorter survival than TCL1-Tg mice. Leukemia cells of TCL1 x BAFF-Tg mice had similar proportions of proliferating cells, but fewer proportions of dying cells, than did the CLL cells of TCL1-Tg mice. Moreover, leukemia cells from either TCL1 x BAFF-Tg or TCL1-Tg mice produced more aggressive disease when transferred into BAFF-Tg mice than into wild-type (WT) mice. Neutralization of CD257 resulted in rapid reduction in circulating leukemia cells.
Summary
SymbolTNFSF13B
Nametumor necrosis factor (ligand) superfamily, member 13b
Aliases BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location13q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNFSF13B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNFSF13B
Nametumor necrosis factor (ligand) superfamily, member 13b
Aliases BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location13q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNFSF13B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2590.642
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2880.866
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2450.843
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0440.941
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2040.9
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1610.934
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5860.25
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8020.556
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3130.841
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9640.457
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8740.675
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1060.568
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNFSF13B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNFSF13B
Nametumor necrosis factor (ligand) superfamily, member 13b
Aliases BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location13q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFSF13B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNFSF13B
Nametumor necrosis factor (ligand) superfamily, member 13b
Aliases BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location13q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFSF13B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFSF13B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNFSF13B
Nametumor necrosis factor (ligand) superfamily, member 13b
Aliases BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location13q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFSF13B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNFSF13B
Nametumor necrosis factor (ligand) superfamily, member 13b
Aliases BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location13q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNFSF13B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNFSF13B
Nametumor necrosis factor (ligand) superfamily, member 13b
Aliases BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location13q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNFSF13B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNFSF13B
Nametumor necrosis factor (ligand) superfamily, member 13b
Aliases BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location13q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNFSF13B collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TNFSF13B.
ID Name Drug Type Targets #Targets
DB033161,4-Diethylene DioxideSmall MoleculeEPN1, TGFB3, TNFSF13B3
DB04272Citric AcidSmall MoleculeAKR1B1, ANG, APRT, BHMT, C8G, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A ......23
DB08879BelimumabBiotechTNFSF13B1